Laura Francis Sells 757 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN - Get Free Report) CEO Laura Francis sold 757 shares of the company's stock in a transaction on Monday, July 7th. The shares were sold at an average price of $18.26, for a total value of $13,822.82. Following the transaction, the chief executive officer directly owned 362,141 shares in the company, valued at $6,612,694.66. This trade represents a 0.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Laura Francis also recently made the following trade(s):

• On Monday, May 19th, Laura Francis sold 5,412 shares of SiBone stock. The shares were sold at an average price of $19.49, for a total value of $105,479.88.
• On Friday, May 16th, Laura Francis sold 12,385 shares of SiBone stock. The shares were sold at an average price of $19.67, for a total value of $243,612.95.
• On Wednesday, May 7th, Laura Francis sold 38,504 shares of SiBone stock. The shares were sold at an average price of $17.18, for a total value of $661,498.72.

SiBone Stock Performance

Shares of SIBN traded up $0.34 during mid-day trading on Thursday, reaching $18.78. The company's stock had a trading volume of 294,940 shares, compared to its average volume of 393,604. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05. The stock has a market cap of $800.40 million, a P/E ratio of -29.34 and a beta of 0.93. The business has a 50-day simple moving average of $18.17 and a two-hundred day simple moving average of $16.29. The company has a current ratio of 8.53, a quick ratio of 7.26 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. The business had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. As a group, equities research analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Finally, Truist Financial raised their price target on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th.

Hedge Funds Weigh In On SiBone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SIBN. Nuveen LLC acquired a new position in SiBone in the 1st quarter valued at $18,605,000. First Light Asset Management LLC raised its holdings in SiBone by 41.8% in the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company's stock valued at $22,622,000 after acquiring an additional 475,426 shares in the last quarter. Silvercrest Asset Management Group LLC raised its holdings in shares of SiBone by 21.9% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock worth $27,392,000 after buying an additional 350,970 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of SiBone by 11.1% during the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company's stock worth $37,072,000 after buying an additional 264,254 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of SiBone by 55.0% during the 1st quarter. Victory Capital Management Inc. now owns 631,568 shares of the company's stock worth $8,861,000 after buying an additional 224,190 shares in the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.